Eslicarbazepine Acetate Tablet
NDC 59651-535
Product Information
Eslicarbazepine Acetate is a ANDA-approved product labeled by Aurobindo Pharma Limited. Eslicarbazepine is used alone or with other medications to treat a certain type of seizure disorder (focal seizures). It is supplied as a white tablet for oral administration. This product entry covers the primary NDC 59651-535 and its associated package configuration. This profile includes active and inactive ingredient UNII references and FDA labeling data.
Primary Identification
Clinical Specifications
Labeler & Regulatory Data
Marketing Timeline
Product Characteristics
ROUND (C48348)
17 MM
E;T;200
ET;400
E;T;600
1
Code Structure Chart
Product Details
What is NDC 59651-535?
What are the uses of this product?
What are Active Ingredients of this product?
Which are the associated UNII Codes?
The UNII codes for the active ingredients in this product are:
- ESLICARBAZEPINE ACETATE (UNII: BEA68ZVB2K)
- ESLICARBAZEPINE (UNII: S5VXA428R4) (Active Moiety)
Which are the Inactive Ingredients associated UNII Codes?
The inactive ingredients are all the component of a medicinal product OTHER than the active ingredient(s). The acronym "UNII" stands for “Unique Ingredient Identifier” and is used to identify each inactive ingredient present in a product. The UNII codes for the inactive ingredients in this product are:
- SILICON DIOXIDE (UNII: ETJ7Z6XBU4)
- CROSPOVIDONE (120 .MU.M) (UNII: 68401960MK)
- MAGNESIUM STEARATE (UNII: 70097M6I30)
- POVIDONE K90 (UNII: RDH86HJV5Z)
- SODIUM STARCH GLYCOLATE TYPE A (UNII: H8AV0SQX4D)
Which are the Pharmacologic Classes of this product?
* Please review the full disclaimer at the bottom of this page.
Patient Education
Eslicarbazepine
Eslicarbazepine is used in combination with other medications to control focal (partial) seizures (seizures that involve only one part of the brain). Eslicarbazepine is in a class of medications called anticonvulsants. It works by decreasing abnormal excitement in the brain.
[Learn More]
* Please review the full disclaimer at the bottom of this page.